All In Biotech

Drug Trial Radar · NCT05001269

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Feb 22, 2022

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.

Conditions

  • Primary Hyperoxaluria
  • Primary Hyperoxaluria Type 1
  • Primary Hyperoxaluria Type 2
  • Primary Hyperoxaluria Type 3

Interventions

  • nedosiranDrug

    Monthly subcutaneous dosing throughout study period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant SubgroupsTime frame: Baseline (Week 0), Month 6
  2. Absolute Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant SubgroupsTime frame: Baseline (Week 0), Month 6

Locations

13 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Research Site

    Rochester, Minnesota

  • Clinical Research Site

    Hamilton, Ontario, Canada

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Research Site

    Heidelberg, Germany

  • Clinical Trial Site

    Roma, Italy

  • Clinical Research Site

    Fukuoka, Japan

  • Clinical Research Site

    Nagoya, Japan

  • Clinical Research Site

    Beirut, Lebanon

  • Clinical Research Site

    Bialystok, Poland

  • Clinical Research Site

    Barcelona, Spain

  • Clinical Research Site

    Yenimahalle, Ankara, Turkey (Türkiye)

  • Clinical Trial Site

    Dubai, United Arab Emirates

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.